Where disease pathogenesis meets protein formulation: Renal deposition of immunoglobulin aggregates

被引:46
作者
Demeule, B [1 ]
Gumy, R [1 ]
Arvinte, T [1 ]
机构
[1] Univ Geneva, Sch Pharmaceut Sci, EPGL, CH-1211 Geneva 4, Switzerland
关键词
immunoglobulin; aggregation; disease; formulation; therapeutic proteins; amyloid;
D O I
10.1016/j.ejpb.2005.08.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aggregation is one of the important issues encountered during the development of immunoglobulin-based drugs. The aim of the current review is to discuss the causes and consequences of immunoglobulin aggregation as well as the relevance of immunoglobulin aggregation to disease pathogenesis. Extracellular deposition of immunoglobulins, either monoclonal light chains or intact polyclonal antibodies, induces renal failure in various nephropathies. The aggregates can present fibrillar or amorphous structures. In this review, factors known to influence protein aggregation, such as the primary structure of the protein, local environment and glycosylation are assessed, as well as the subsequent altered clearance, fibril formation and toxicity. The role of the protein local environment is emphasized. Even if the local environment causes only minor perturbations in the protein structure, these perturbations might be sufficient to trigger aggregate formation. This fact underlines the importance of choosing appropriate formulations for protein drugs. If the formulation provides a slightly destabilizing environment to the protein, the long-term stability of the drug may be compromised by aggregate formation. (c) 2005 Published by Elsevier B.V.
引用
收藏
页码:121 / 130
页数:10
相关论文
共 93 条
  • [81] Protein conformation and disease: Pathological consequences of analogous mutations in homologous proteins
    Stevens, FJ
    Pokkuluri, PR
    Schiffer, M
    [J]. BIOCHEMISTRY, 2000, 39 (50) : 15291 - 15296
  • [82] STEVENS FJ, 2000, Patent No. 6063636
  • [83] Expression and physical association of Fcα receptor and Fc receptor γ chain in human mesangial cells
    Suzuki, Y
    Ra, C
    Saito, K
    Horikoshi, S
    Hasegawa, S
    Tsuge, T
    Okumura, K
    Tomino, Y
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (05) : 1117 - 1123
  • [84] Tagouri YM, 1996, LAB INVEST, V74, P290
  • [85] Establishment of a first-order kinetic model of light chain-associated amyloid fibril extension in vitro
    Takahashi, N
    Hasegawa, K
    Yamaguchi, I
    Okada, H
    Ueda, T
    Gejyo, F
    Naiki, H
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2002, 1601 (01): : 110 - 120
  • [86] Monocyte chemoattractant protein (MCP)-1 production via functionally reconstituted Fcα receptor (CD89) on glomerular mesangial cells
    Tsuge, T
    Suzuki, I
    Shimokawa, T
    Horikoshi, S
    Okumura, K
    Ra, C
    Tomino, Y
    [J]. INFLAMMATION RESEARCH, 2003, 52 (10) : 428 - 432
  • [87] Thermodynamic instability of human λ6 light chains:: Correlation with fibrillogenicity
    Wall, J
    Schell, M
    Murphy, C
    Hrncic, R
    Stevens, FJ
    Solomon, A
    [J]. BIOCHEMISTRY, 1999, 38 (42) : 14101 - 14108
  • [88] Wall J, 1999, METHOD ENZYMOL, V309, P204
  • [89] Binding capacity and pathophysiological effects of IgA1 from patients with IgA nephropathy on human glomerular mesangial cells
    Wang, Y
    Zhao, MH
    Zhang, YK
    Li, XM
    Wang, HY
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2004, 136 (01) : 168 - 175
  • [90] WESTERMARK GT, 1991, CLIN EXP IMMUNOL, V86, P150